EUVIMEDEUVIMED entdecken
Kommentar

Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169 572 per QALY and exenatide with $278 935 per QALY as second-line treatment in adult diabetics in the USA

Wendy A Davis

Evidence Based Medicine · 2010-04 · 15 (2) · 40-41

DOI: 10.1136/ebm1034 ↗

Kurz gefasst

Kommentar in der Zeitschrift Evidence Based Medicine, online erschienen am 01.05.2010. Verfasst von Wendy A Davis. Beteiligte Einrichtung: University of Western Australia, School of Medicine and Pharmacology, Fremantle Hospital, PO Box 480, Fremantle WA 6959, Australia. wdavis@meddent.uw…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • University of Western Australia, School of Medicine and Pharmacology, Fremantle Hospital, PO Box 480, Fremantle WA 6959, Australia. wdavis@meddent.uwa.edu.au

Zitieren

APA

Davis, W. A. (2010). Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169 572 per QALY and exenatide with $278 935 per QALY as second-line treatment in adult diabetics in the USA. Evidence Based Medicine, 15(2), 40-41. https://doi.org/10.1136/ebm1034

Vancouver

Davis WA. Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169 572 per QALY and exenatide with $278 935 per QALY as second-line treatment in adult diabetics in the USA. Evidence Based Medicine. 2010;15(2):40-41. doi:10.1136/ebm1034

BibTeX
@article{Davis2010,
  author = {Davis, Wendy A},
  title = {Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169 572 per QALY and exenatide with $278 935 per QALY as second-line treatment in adult diabetics in the USA},
  journal = {Evidence Based Medicine},
  year = {2010},
  volume = {15},
  number = {2},
  pages = {40--41},
  doi = {10.1136/ebm1034}
}
Kostenlos starten →